Revolade (Eltrombopag)
eltrombopag 50 mg tablet, 28 · ORAL · PBS code 14143J
AUTHORITY_REQUIREDWhat it costs
AU$2456.24 PBS-determined price per 84 units
Most patients pay only the standard PBS co-payment, not the full price above — up to AU$25.00 per script (general) or AU$7.70 (concession/Safety Net) in 2026. The figure above is what the PBS pays the pharmacy; the Australian Government subsidises the rest. Always confirm the current amount with your pharmacist.
- • First listed on the PBS: 2024-05-01.
- • Repeats: 5.
- • PBS program: HS.
Eligibility criteria for subsidised access
The following is the government's own wording from the PBS Schedule, shown unchanged.
Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1
Severe aplastic anaemia
Continuing treatment - Second line treatment
The condition must be severe aplastic anaemia; AND
Patient must have previously received PBS-subsidised treatment with this drug for this condition under the initial treatment restriction; AND
Patient must have demonstrated a response to PBS-subsidised treatment with this drug.
Platelet, haemoglobin and neutrophil counts must be no more than 4 weeks old at the time of application and must be documented in the patient's medical records.
Once platelet count is greater than 50 x 109/L, haemoglobin is greater than 100 g/L in the absence of red blood cell (RBC) transfusion, and absolute neutrophil (ANC) is greater than 1 x 109/L for more than 8 weeks, the dose of eltrombopag should be reduced as per the Product Information.
For the purposes of this restriction, a response is defined as no longer meeting the criteria for severe aplastic anaemia.
Sponsor: Novartis Pharmaceuticals Australia Pty Limited ABN 18 004 244 160
Not medical advice. Voxsanity republishes public PBS data in plain English. PBS listing status and criteria can change; always confirm current subsidised availability with your doctor or pharmacist.
Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.